New perspectives in the treatment of cushing's syndrome

Regardless of etiology, all cases of endogenous Cushing's syndrome are due to increased production of cortisol by the adrenal gland. Most are caused by adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas. Alternatively, the glucocorticoid excess may be due to adrenal neoplasia or t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labeur, Marta Susana, Páez Pereda, Marcelo
Publicado:	2004
Materias:	ACTH Cushing's syndrome Glucocorticoids HPA axis POMC 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 2 (2 amino 3 methoxyphenyl)chromone 4 aminobutyrate aminotransferase inhibitor aminoglutethimide bromocriptine cabergoline corticotropin corticotropin releasing factor corticotropin releasing factor antagonist cyproheptadine cytokine receptor dopamine derivative dopamine receptor stimulating agent glucocorticoid glucocorticoid antagonist glucocorticoid receptor antagonist hormone receptor blocking agent ketoconazole metyrapone mitotane n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide octreotide retinoic acid rosiglitazone serotonin antagonist somatostatin derivative unindexed drug uo 126 valproic acid adrenal disease adrenal function alopecia amenorrhea blood clotting disorder clinical trial corticotropin release Cushing syndrome depression diarrhea dizziness dose response drug efficacy drug eruption drug targeting gastrointestinal symptom glucose blood level headache hormonal regulation hormone substitution human hydrocortisone release hyperglycemia hypertension hypogonadism hypophysis adenoma hypothalamus hypophysis adrenal system increased appetite liver toxicity molecular biology morbidity mortality muscle hypotonia muscle weakness myalgia nausea nonhuman obesity osteoporosis pathogenesis pruritus psychopathy review side effect signal transduction somnolence taste disorder transcription regulation transsphenoidal hypophysectomy vomiting xerostomia Adrenocorticotropic Hormone Animals Cushing Syndrome Drug Delivery Systems Humans Receptors, Corticotropin-Releasing Hormone
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15680088_v4_n4_p335_Labeur http://hdl.handle.net/20.500.12110/paper_15680088_v4_n4_p335_Labeur
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_15680088_v4_n4_p335_Labeur
record_format	dspace
spelling	paper:paper_15680088_v4_n4_p335_Labeur2023-06-08T16:24:08Z New perspectives in the treatment of cushing's syndrome Labeur, Marta Susana Páez Pereda, Marcelo ACTH Cushing's syndrome Glucocorticoids HPA axis POMC 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 2 (2 amino 3 methoxyphenyl)chromone 4 aminobutyrate aminotransferase inhibitor aminoglutethimide bromocriptine cabergoline corticotropin corticotropin releasing factor corticotropin releasing factor antagonist cyproheptadine cytokine receptor dopamine derivative dopamine receptor stimulating agent glucocorticoid glucocorticoid antagonist glucocorticoid receptor antagonist hormone receptor blocking agent ketoconazole metyrapone mitotane n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide octreotide retinoic acid rosiglitazone serotonin antagonist somatostatin derivative unindexed drug uo 126 valproic acid adrenal disease adrenal function alopecia amenorrhea blood clotting disorder clinical trial corticotropin release Cushing syndrome depression diarrhea dizziness dose response drug efficacy drug eruption drug targeting gastrointestinal symptom glucose blood level headache hormonal regulation hormone substitution human hydrocortisone release hyperglycemia hypertension hypogonadism hypophysis adenoma hypothalamus hypophysis adrenal system increased appetite liver toxicity molecular biology morbidity mortality muscle hypotonia muscle weakness myalgia nausea nonhuman obesity osteoporosis pathogenesis pruritus psychopathy review side effect signal transduction somnolence taste disorder transcription regulation transsphenoidal hypophysectomy vomiting xerostomia Adrenocorticotropic Hormone Animals Cushing Syndrome Drug Delivery Systems Humans Receptors, Corticotropin-Releasing Hormone Regardless of etiology, all cases of endogenous Cushing's syndrome are due to increased production of cortisol by the adrenal gland. Most are caused by adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas. Alternatively, the glucocorticoid excess may be due to adrenal neoplasia or to ectopic ACTH-secreting tumors. Cushing's syndrome is characterized by endocrine and metabolic alterations such as truncal obesity, hypertension, weakness, amenorrhea, hyperglycemia, osteoporosis and depression. Unless treated, the disease is associated with high morbidity, and ultimately, mortality. Depending on the etiology of Cushing's syndrome two different treatment modalities are possible: reduction of pituitary ACTH production or reduction of adrenocortical cortisol secretion. In the absence of efficient drug therapy, transsphenoidal resection of the pituitary adenoma is the primary treatment of choice for the reduction of ACTH secretion. In the last years there was much progress in understanding the molecular mechanisms that control the function of the hypothalamic-pituitary-adrenal axis. Thus, new insights made it possible to identify potential drug targets for the treatment of Cushing's syndrome. The present article reviews different drug targets and therapeutic options including drugs that control the central ACTH regulation, e.g. by modulating signaling pathways and transcriptional regulation of ACTH biosynthesis, corticotrophin releasing hormone (CRH) or glucocorticoid receptor antagonists, inhibitors of glucocorticoid synthesis, ketoconazole, somatostatin and dopamine analogs. Some of these substances might be useful for the treatment of Cushing's syndrome. © 2004 Bentham Science Publishers Ltd. Fil:Labeur, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Péz-Pereda, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2004 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15680088_v4_n4_p335_Labeur http://hdl.handle.net/20.500.12110/paper_15680088_v4_n4_p335_Labeur
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	ACTH Cushing's syndrome Glucocorticoids HPA axis POMC 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 2 (2 amino 3 methoxyphenyl)chromone 4 aminobutyrate aminotransferase inhibitor aminoglutethimide bromocriptine cabergoline corticotropin corticotropin releasing factor corticotropin releasing factor antagonist cyproheptadine cytokine receptor dopamine derivative dopamine receptor stimulating agent glucocorticoid glucocorticoid antagonist glucocorticoid receptor antagonist hormone receptor blocking agent ketoconazole metyrapone mitotane n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide octreotide retinoic acid rosiglitazone serotonin antagonist somatostatin derivative unindexed drug uo 126 valproic acid adrenal disease adrenal function alopecia amenorrhea blood clotting disorder clinical trial corticotropin release Cushing syndrome depression diarrhea dizziness dose response drug efficacy drug eruption drug targeting gastrointestinal symptom glucose blood level headache hormonal regulation hormone substitution human hydrocortisone release hyperglycemia hypertension hypogonadism hypophysis adenoma hypothalamus hypophysis adrenal system increased appetite liver toxicity molecular biology morbidity mortality muscle hypotonia muscle weakness myalgia nausea nonhuman obesity osteoporosis pathogenesis pruritus psychopathy review side effect signal transduction somnolence taste disorder transcription regulation transsphenoidal hypophysectomy vomiting xerostomia Adrenocorticotropic Hormone Animals Cushing Syndrome Drug Delivery Systems Humans Receptors, Corticotropin-Releasing Hormone
spellingShingle	ACTH Cushing's syndrome Glucocorticoids HPA axis POMC 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 2 (2 amino 3 methoxyphenyl)chromone 4 aminobutyrate aminotransferase inhibitor aminoglutethimide bromocriptine cabergoline corticotropin corticotropin releasing factor corticotropin releasing factor antagonist cyproheptadine cytokine receptor dopamine derivative dopamine receptor stimulating agent glucocorticoid glucocorticoid antagonist glucocorticoid receptor antagonist hormone receptor blocking agent ketoconazole metyrapone mitotane n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide octreotide retinoic acid rosiglitazone serotonin antagonist somatostatin derivative unindexed drug uo 126 valproic acid adrenal disease adrenal function alopecia amenorrhea blood clotting disorder clinical trial corticotropin release Cushing syndrome depression diarrhea dizziness dose response drug efficacy drug eruption drug targeting gastrointestinal symptom glucose blood level headache hormonal regulation hormone substitution human hydrocortisone release hyperglycemia hypertension hypogonadism hypophysis adenoma hypothalamus hypophysis adrenal system increased appetite liver toxicity molecular biology morbidity mortality muscle hypotonia muscle weakness myalgia nausea nonhuman obesity osteoporosis pathogenesis pruritus psychopathy review side effect signal transduction somnolence taste disorder transcription regulation transsphenoidal hypophysectomy vomiting xerostomia Adrenocorticotropic Hormone Animals Cushing Syndrome Drug Delivery Systems Humans Receptors, Corticotropin-Releasing Hormone Labeur, Marta Susana Páez Pereda, Marcelo New perspectives in the treatment of cushing's syndrome
topic_facet	ACTH Cushing's syndrome Glucocorticoids HPA axis POMC 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 2 (2 amino 3 methoxyphenyl)chromone 4 aminobutyrate aminotransferase inhibitor aminoglutethimide bromocriptine cabergoline corticotropin corticotropin releasing factor corticotropin releasing factor antagonist cyproheptadine cytokine receptor dopamine derivative dopamine receptor stimulating agent glucocorticoid glucocorticoid antagonist glucocorticoid receptor antagonist hormone receptor blocking agent ketoconazole metyrapone mitotane n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide octreotide retinoic acid rosiglitazone serotonin antagonist somatostatin derivative unindexed drug uo 126 valproic acid adrenal disease adrenal function alopecia amenorrhea blood clotting disorder clinical trial corticotropin release Cushing syndrome depression diarrhea dizziness dose response drug efficacy drug eruption drug targeting gastrointestinal symptom glucose blood level headache hormonal regulation hormone substitution human hydrocortisone release hyperglycemia hypertension hypogonadism hypophysis adenoma hypothalamus hypophysis adrenal system increased appetite liver toxicity molecular biology morbidity mortality muscle hypotonia muscle weakness myalgia nausea nonhuman obesity osteoporosis pathogenesis pruritus psychopathy review side effect signal transduction somnolence taste disorder transcription regulation transsphenoidal hypophysectomy vomiting xerostomia Adrenocorticotropic Hormone Animals Cushing Syndrome Drug Delivery Systems Humans Receptors, Corticotropin-Releasing Hormone
description	Regardless of etiology, all cases of endogenous Cushing's syndrome are due to increased production of cortisol by the adrenal gland. Most are caused by adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas. Alternatively, the glucocorticoid excess may be due to adrenal neoplasia or to ectopic ACTH-secreting tumors. Cushing's syndrome is characterized by endocrine and metabolic alterations such as truncal obesity, hypertension, weakness, amenorrhea, hyperglycemia, osteoporosis and depression. Unless treated, the disease is associated with high morbidity, and ultimately, mortality. Depending on the etiology of Cushing's syndrome two different treatment modalities are possible: reduction of pituitary ACTH production or reduction of adrenocortical cortisol secretion. In the absence of efficient drug therapy, transsphenoidal resection of the pituitary adenoma is the primary treatment of choice for the reduction of ACTH secretion. In the last years there was much progress in understanding the molecular mechanisms that control the function of the hypothalamic-pituitary-adrenal axis. Thus, new insights made it possible to identify potential drug targets for the treatment of Cushing's syndrome. The present article reviews different drug targets and therapeutic options including drugs that control the central ACTH regulation, e.g. by modulating signaling pathways and transcriptional regulation of ACTH biosynthesis, corticotrophin releasing hormone (CRH) or glucocorticoid receptor antagonists, inhibitors of glucocorticoid synthesis, ketoconazole, somatostatin and dopamine analogs. Some of these substances might be useful for the treatment of Cushing's syndrome. © 2004 Bentham Science Publishers Ltd.
author	Labeur, Marta Susana Páez Pereda, Marcelo
author_facet	Labeur, Marta Susana Páez Pereda, Marcelo
author_sort	Labeur, Marta Susana
title	New perspectives in the treatment of cushing's syndrome
title_short	New perspectives in the treatment of cushing's syndrome
title_full	New perspectives in the treatment of cushing's syndrome
title_fullStr	New perspectives in the treatment of cushing's syndrome
title_full_unstemmed	New perspectives in the treatment of cushing's syndrome
title_sort	new perspectives in the treatment of cushing's syndrome
publishDate	2004
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15680088_v4_n4_p335_Labeur http://hdl.handle.net/20.500.12110/paper_15680088_v4_n4_p335_Labeur
work_keys_str_mv	AT labeurmartasusana newperspectivesinthetreatmentofcushingssyndrome AT paezperedamarcelo newperspectivesinthetreatmentofcushingssyndrome
_version_	1768543867070578688

New perspectives in the treatment of cushing's syndrome

Ejemplares similares